RxDoctor Payments Data

James Joyner, MD

Infectious Disease · Honolulu, HINPI 1184704355

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.6% of the total across 90 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Insmed, Inc. accounts for 72.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $412 and has fallen 66.8% since, to $137 in 2025.

$1,522in general payments, 2019–2025

Across 90 payments — averaging $16.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Insmed, Inc.$1K
  • AbbVie$275
  • Viiv Healthcare Company$74
  • Johnson & Johnson$37
  • Gilead$20
  • Merck$13

What the payments were for

  • Food & beverage$1,44095%
  • Education$835%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Insmed, Inc.67$1,104
AbbVie(2 entities)16$275
Viiv Healthcare Company3$74
Johnson & Johnson2$37
Gilead1$20
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,522 in reported general payments places this provider in the 60th percentile of 28 infectious disease providers in Hawaii.

See all infectious disease providers in Hawaii

Medicare billing

Part B allowed, 2024
$202,890
Medicare patients
247
Services billed
1,821

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin32$54,343
DovatoDolutegravir Sodium/Lamivudine17$51,140
ErtapenemErtapenem Sodium51$29,380
CeftriaxoneCeftriaxone Sodium21$6,654
Fosfomycin Tromethamine26$6,565
Vancomycin Hcl13$6,435
Azithromycin46$4,436
Meropenem16$3,806
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav57$3,193
Ethambutol Hcl41$1,532
Voriconazole14$1,463
Cephalexin18$1,299
Minocycline Hcl40$1,181
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst22$1,176
Doxycycline Hyclate42$943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyDovato$74$51,14017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 28 infectious disease providers in Hawaii.

Other infectious disease in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →